For Our Patients

---

Orlando, Florida, Wednesday, March 3, 2022

NEWS!

Today we are extremely honored to share Florida Retina Institute’s Matthew A. Cunningham, MD, FASRS, and his research team are the first to enroll a patient in the United States into the ML43435/Elevatum study.

What is the
Elevatum Study?

Elevatum is a USMA sponsored PhIV study with faricimab (VABYSMO) for underrepresented patients with Diabetic Macular Edema, DME.

It is the first inclusive research study for Ophthalmology.

The impact of Elevatum in our patient populations spans beyond the expansion of our understanding about faricimab.

Faricimab is the first investigational bispecific antibody designed for the eye.

Faricimab, sold under the brand name Vabysmo, is a monoclonal antibody used for the treatment of neovascular age-related macular degeneration and diabetic macular edema.

Faricimab is the first bispecific monoclonal antibody, to target both vascular endothelial growth factor, and angiopoietin 2 inhibitor.

Congratulations to Dr. Cunningham and Florida Retina Institute’s research team on this outstanding accomplishment!

Matthew A. Cunningham, MD, FASRS, is the Primary Investigator and Clinical Research Director, Central Florida Region Clinical Research, Florida Retina Institute

---